QQQ   443.95 (-0.20%)
AAPL   170.99 (-1.34%)
MSFT   420.05 (-0.33%)
META   486.80 (-1.43%)
GOOGL   150.66 (-0.14%)
AMZN   180.14 (+0.17%)
TSLA   177.08 (-1.53%)
NVDA   905.81 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.74 (+0.64%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.19 (+1.00%)
MU   117.75 (-1.17%)
CGC   9.37 (-1.88%)
GE   174.62 (-3.05%)
DIS   122.44 (+1.21%)
AMC   3.69 (-14.98%)
PFE   28.04 (+0.94%)
PYPL   67.19 (+0.93%)
XOM   115.86 (+0.77%)
QQQ   443.95 (-0.20%)
AAPL   170.99 (-1.34%)
MSFT   420.05 (-0.33%)
META   486.80 (-1.43%)
GOOGL   150.66 (-0.14%)
AMZN   180.14 (+0.17%)
TSLA   177.08 (-1.53%)
NVDA   905.81 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.74 (+0.64%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.19 (+1.00%)
MU   117.75 (-1.17%)
CGC   9.37 (-1.88%)
GE   174.62 (-3.05%)
DIS   122.44 (+1.21%)
AMC   3.69 (-14.98%)
PFE   28.04 (+0.94%)
PYPL   67.19 (+0.93%)
XOM   115.86 (+0.77%)
QQQ   443.95 (-0.20%)
AAPL   170.99 (-1.34%)
MSFT   420.05 (-0.33%)
META   486.80 (-1.43%)
GOOGL   150.66 (-0.14%)
AMZN   180.14 (+0.17%)
TSLA   177.08 (-1.53%)
NVDA   905.81 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.74 (+0.64%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.19 (+1.00%)
MU   117.75 (-1.17%)
CGC   9.37 (-1.88%)
GE   174.62 (-3.05%)
DIS   122.44 (+1.21%)
AMC   3.69 (-14.98%)
PFE   28.04 (+0.94%)
PYPL   67.19 (+0.93%)
XOM   115.86 (+0.77%)
QQQ   443.95 (-0.20%)
AAPL   170.99 (-1.34%)
MSFT   420.05 (-0.33%)
META   486.80 (-1.43%)
GOOGL   150.66 (-0.14%)
AMZN   180.14 (+0.17%)
TSLA   177.08 (-1.53%)
NVDA   905.81 (+0.37%)
NIO   4.55 (-2.57%)
AMD   180.74 (+0.64%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.19 (+1.00%)
MU   117.75 (-1.17%)
CGC   9.37 (-1.88%)
GE   174.62 (-3.05%)
DIS   122.44 (+1.21%)
AMC   3.69 (-14.98%)
PFE   28.04 (+0.94%)
PYPL   67.19 (+0.93%)
XOM   115.86 (+0.77%)
OTCMKTS:GNWSF

StageZero Life Sciences (GNWSF) Stock Price, News & Analysis

$0.04
+0.01 (+33.33%)
(As of 03/27/2024 ET)
Today's Range
$0.03
$0.04
50-Day Range
$0.03
$0.03
52-Week Range
$0.00
$1.27
Volume
55,300 shs
Average Volume
26,719 shs
Market Capitalization
$2.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GNWSF stock logo

About StageZero Life Sciences Stock (OTCMKTS:GNWSF)

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.

GNWSF Stock Price History

GNWSF Stock News Headlines

Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
In life sciences, Boston continues to reign supreme
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
See More Headlines
Receive GNWSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic Substances
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNWSF
Fax
N/A
Employees
51
Year Founded
N/A

Profitability

Net Income
$-6,860,000.00
Net Margins
-200.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.15 million
Book Value
($0.02) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.52 million
Optionable
Not Optionable
Beta
0.28
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. James R. Howard-Tripp
    Exec. Chairman & CEO
  • Mr. Carl Solomon
    Interim Chief Financial Officer
  • Prof. Choong-Chin Liew
    Co-Founder
  • Mr. Warren Whitehead C.M.A. (Age 69)
    Chief Accountant
  • Mr. David Suria
    Sr. Scientist

GNWSF Stock Analysis - Frequently Asked Questions

How have GNWSF shares performed in 2024?

StageZero Life Sciences' stock was trading at $0.0294 on January 1st, 2024. Since then, GNWSF shares have increased by 36.1% and is now trading at $0.04.
View the best growth stocks for 2024 here
.

How do I buy shares of StageZero Life Sciences?

Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:GNWSF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners